Syngene International Limited — JV/Acquisition, 10-03-2025: Acquisition

Syngene International Limited will invest up to USD 56 million in its fully owned subsidiary, Syngene USA Inc (SUSA), to finance the acquisition of a biologics facility and support operational expenses. SUSA, incorporated in Delaware, recorded a turnover of approximately USD 73.32 lakh in FY 2023-24. This strategic investment aims to enhance the company's presence in the US market, with completion expected by March 31, 2026. The investment will not alter ownership stakes, as SUSA remains a wholly owned subsidiary. This move is poised to strengthen Syngene's operational capabilities in the growing biopharmaceutical sector.